CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
异体 CAR-T 细胞：复杂细胞治疗设计考验临床前模型的极限
英文原题：Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models.
查看英文原题
Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
目前所有获FDA批准的嵌合抗原受体（CAR）T细胞产品均为自体产品，这为广泛应用带来了若干挑战。本期中，Degagn及其同事报告了一项关于开发多发性骨髓瘤现货型CAR-T 细胞的临床前研究。他们利用CRISPR/Cas12a基因组编辑平台和基因敲入技术，消除同种异体反应性并降低细胞被自然杀伤（NK）细胞清除的易感性。该研究促成了一项正在开展的现货型CAR-T 细胞治疗多发性骨髓瘤I期临床试验。相关研究见Degagn等，第462页（2）。
展开英文摘要原文
All chimeric antigen receptor (CAR) T-cell products currently approved by the FDA are autologous, which poses several challenges for widespread use. In this issue, Degagn and colleagues present their preclinical research on creating off-the-shelf CAR T cells for multiple myeloma.
They utilized the CRISPR/Cas12a genome editing platform and gene knock-in techniques to eliminate alloreactivity and decrease susceptibility to natural killer (NK)-cell elimination. This work has led to an ongoing phase I trial of off-the-shelf CAR T cells for multiple myeloma treatment. See related article by Degagn et al. , p. 462 (2).
论文信息
- 作者
- Caimi PF、Melenhorst JJ
- 第一作者单位
- Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio.United States
- 通讯作者单位
- Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.United States
- 文献类型
- 评论
- 期刊
- Cancer immunology research2024 Apr 2
- 原文标识
- PubMed 38562081 · DOI 10.1158/2326-6066.CIR-24-0204